J&J buys Halda Therapeutics for $3.05 billion
Johnson & Johnson expands its oncology portfolio with $3.05 billion acquisition of Halda Therapeutics, strengthening its cancer treatment pipeline. Learn about this major healthcare investment.
Category : Search result: Halda Therapeutics
Boehringer Ingelheim Licenses Novel Autoimmune Treatment
Global pharmaceutical leader Boehringer Ingelheim secures exclusive license from Kyowa Kirin to develop innovative autoimmune disease treatment, targeting conditions like lupus and rheumatoid arthritis with novel therapeutic approach.
Page 1 of 1